10 Best Annual Dividend Stocks To Buy Now

6. Roche Holding AG (OTC:RHHBY)

Dividend Yield as of February 6: 3.33%

Number of Hedge Fund Holders: N/A

Roche Holding AG (OTC:RHHBY) was established in 1896 and is headquartered in Basel, Switzerland. The company develops treatments for cancer, autoimmune diseases, neurological disorders, respiratory conditions, and more. The company also offers in-vitro diagnostic tests, medical instruments, and digital health solutions for diseases like cancer, diabetes, and COVID-19.

On February 7, Roche’s phase III REGENCY trial found that Gazyva/Gazyvaro significantly improved renal response in lupus nephritis patients, with 46.4% achieving complete renal response (CRR) vs. 33.1% on standard therapy. The drug also reduced inflammation markers, potentially preserving kidney function. Gazyva/Gazyvaro is the first anti-CD20 monoclonal antibody in a phase III study to show CRR benefits, as published in the New England Journal of Medicine.

In 2024, Roche Holding AG (OTC:RHHBY)’s sales grew by 7% to CHF 60.5 billion. There was solid momentum across the Pharmaceuticals and Diagnostics divisions, which made up for the decline in COVID-related sales of CHF 1.1 billion. Roche’s core operating profit surged 14%, driven by higher sales, better margins, and cost efficiency. On top of that, operating free cash flow surged 34% to CHF 20.1 billion, giving Roche a strong financial position for future investments. Looking ahead, Roche expects mid-single-digit sales growth in 2025 and aims to increase its dividend for the 38th consecutive year to CHF 9.70. It is one of the best dividend stocks to consider for an income portfolio.